



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

产品名称: **PF 543 HCl**
CAS 号: **1706522-79-3**
产品货号: **S89988**

生物活性:

Description	PF-543 hydrochloride (Sphingosine Kinase 1 Inhibitor II hydrochloride) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC ₅₀ of 2 nM and a K _i of 3.6 nM. PF-543 hydrochloride is >100-fold selectivity for SPHK1 over SPHK2. PF-543 hydrochloride is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC ₅₀ of 26.7 nM. PF-543 hydrochloride induces apoptosis, necrosis, and autophagy[1][2][3].																
IC₅₀ & Target	SphK1																
In Vitro	PF-543 (10-1000 nM; 24 hours; PASM cells) treatment abolishes SK1 expression at nM concentrations[2]. PF-543 (0.1-10 μM; 24 hours; PASM cells) treatment induces caspase-3/7 activity[2]. PF-543 inhibits C17-S1P formation in 1483 cells with an IC₅₀ of 1.0 nM[1]. SphK1 inhibition by PF-543 causes a dose-dependent depletion of the intracellular level of S1P with EC₅₀ concentration of 8.4 nM and a concomitant elevation of the intracellular level of sphingosine in 1483 cells. The level of endogenous S1P in 1483 cells after a 1 h treatment with 200 nM PF-543 is decreased 10-fold, producing a proportional increase in the level of sphingosine[1]. Western Blot Analysis[2] <table><tr><td>Cell Line:</td><td>Human pulmonary arterial smooth muscle (PASM) cells</td></tr><tr><td>Concentration:</td><td>10 nM, 100 nM, 1000 nM</td></tr><tr><td>Incubation Time:</td><td>24 hours</td></tr><tr><td>Result:</td><td>Abolished SK1 expression at nM concentrations.</td></tr></table> Apoptosis Analysis[2] <table><tr><td>Cell Line:</td><td>Human pulmonary arterial smooth muscle (PASM) cells</td></tr><tr><td>Concentration:</td><td>0.1 μM, 1 μM, 10 μM</td></tr><tr><td>Incubation Time:</td><td>24 hours</td></tr><tr><td>Result:</td><td>Induced caspase-3/7 activity in cultured human pulmonary smooth muscle cells.</td></tr></table>	Cell Line:	Human pulmonary arterial smooth muscle (PASM) cells	Concentration:	10 nM, 100 nM, 1000 nM	Incubation Time:	24 hours	Result:	Abolished SK1 expression at nM concentrations.	Cell Line:	Human pulmonary arterial smooth muscle (PASM) cells	Concentration:	0.1 μM, 1 μM, 10 μM	Incubation Time:	24 hours	Result:	Induced caspase-3/7 activity in cultured human pulmonary smooth muscle cells.
Cell Line:	Human pulmonary arterial smooth muscle (PASM) cells																
Concentration:	10 nM, 100 nM, 1000 nM																
Incubation Time:	24 hours																
Result:	Abolished SK1 expression at nM concentrations.																
Cell Line:	Human pulmonary arterial smooth muscle (PASM) cells																
Concentration:	0.1 μM, 1 μM, 10 μM																
Incubation Time:	24 hours																
Result:	Induced caspase-3/7 activity in cultured human pulmonary smooth muscle cells.																
In Vivo	PF-543 (1 mg/kg; intraperitoneal injection; every second day; for 21 days; female C57BL/6 J mice) treatment has no effect on vascular remodelling but reduces right ventricular hypertrophy. The protection involves a reduction in the expression of p53 and an increase in the expression of anti-oxidant nuclear factor Nrf-2[2]. Mice are initially dosed (ip) with 10 mg/kg or 30 mg/kg of PF-543 for 24 h and the T1/2 is 1.2 h in blood samples. Administration of 10 mg/kg PF-543 for 24 h to mice induces a decrease in SK1 expression in pulmonary vessels[2]. <table><tr><td>Animal Model:</td><td>Female C57BL/6 J mice (7-12 week-old) with hypoxic-induced pulmonary arterial hypertension[2]</td></tr><tr><td>Dosage:</td><td>1 mg/kg</td></tr><tr><td>Administration:</td><td>Intraperitoneal injection; every second day; for 21 days</td></tr><tr><td>Result:</td><td>Reduced right ventricular hypertrophy. The protection involves a reduction in the expression of p53 (that promotes cardiomyocyte death) and an increase in the expression of anti-oxidant nuclear factor Nrf-2.</td></tr></table>	Animal Model:	Female C57BL/6 J mice (7-12 week-old) with hypoxic-induced pulmonary arterial hypertension[2]	Dosage:	1 mg/kg	Administration:	Intraperitoneal injection; every second day; for 21 days	Result:	Reduced right ventricular hypertrophy. The protection involves a reduction in the expression of p53 (that promotes cardiomyocyte death) and an increase in the expression of anti-oxidant nuclear factor Nrf-2.								
Animal Model:	Female C57BL/6 J mice (7-12 week-old) with hypoxic-induced pulmonary arterial hypertension[2]																
Dosage:	1 mg/kg																
Administration:	Intraperitoneal injection; every second day; for 21 days																
Result:	Reduced right ventricular hypertrophy. The protection involves a reduction in the expression of p53 (that promotes cardiomyocyte death) and an increase in the expression of anti-oxidant nuclear factor Nrf-2.																
	[1]. Schnute ME, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of																



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

参考文献

- sphingosine kinase-1. Biochem J. 2012 May 15;444(1):79-88.
- [2]. MacRitchie N, et al. Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. Cell Signal. 2016 Aug;28(8):946-55.
- [3]. Hamada M, et al. Induction of autophagy by sphingosine kinase 1 inhibitor PF-543 in head and neck squamous cell carcinoma cells. Cell Death Discov. 2017 Aug 14;3:17047.



源叶